We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide announces results of the annual General Meeting 2026
8 Apr 2026 - Baar, 8 April 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2026
17 Mar 2026 - Baar, 17 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fifth […]
Read morePolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
19 Jan 2026 - Baar, 19 January 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its […]
Read morePolyPeptide showcases leadership in sustainable peptide manufacturing with two landmark publications
19 Dec 2025 - The future of peptide manufacturing isn’t just about making more—it’s about making better. Peptide therapeutics are transforming medicine, but traditional production can be resource-intensive. At PolyPeptide, […]
Read morePolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies
12 Dec 2025 - Baar, 12 December 2025 – PolyPeptide Group AG (SIX: PPGN), a global CDMO for peptide-based APIs, and Lupin Manufacturing Solutions Limited (LMS) have formed a strategic […]
Read morePolyPeptide’s Approach to Process Intensification: Tackling the increasing Peptide Demand
27 Nov 2025 - Presented at TIDES Europe, 12 November 2025 Speaker: Francesco Terzani, Scientist Innovation Abstract: The global rise in peptide demand, driven by accelerated clinical development and speed to […]
Read moreLifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
28 Oct 2025 - Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract […]
Read moreCapacity expansion underway at our Ambernath facility
24 Oct 2025 - We recently announced an investment at our Ambernath facility in India—transforming it into a larger, more diverse site. This expansion is part of PolyPeptide’s strategic growth, […]
Read moreCapacity expansion for major Pharma’s hormonal disorders and women’s health portfolio
29 Sep 2025 - We recently announced a capacity expansion at our Braine-l’Alleud site in Belgium, strategically backed by customer financing. This investment underscores our commitment to capturing growth in […]
Read more